PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO), a biotechnology company, announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year’s American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.
“We are pleased that lead investigator Dr. Ted Mau will have the opportunity to share additional encouraging insights on the safety and immunogenicity of INO-3107 from both cohorts of our recently completed study,” said Dr. Mike Sumner, INOVIO’s Chief Medical Officer.
Details of the ABEA at COSM presentation are as follows:
Title: Phase 1/2 Open-label, Multicenter Trial Of INO-3107 With Electroporation In Adult Patients With HPV-6 And/or HPV-11-associated Recurrent Respiratory Papillomatosis: Interim Analysis
Session: ABEA Scientific Session III: Voice
Session Date and Time: Friday, May 5, 2023, 9:00 am EDT
Location: 304/306 (Hynes)
The presentation will include new safety, immunological, and demographic data from both cohorts of a Phase 1/2 trial evaluating the safety, tolerability, immunogenicity, and efficacy of INO-3107 in 32 patients with HPV-6 and/or HPV-11-associated RRP.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.